Thus, the capability of SHOX2 and SEPT9 methylation to distinguish between malignant and paramalignant ascites was evaluated in a subgroup of cancer patients by comparing the survival in positive versus negative patients. This evidence concerns the gene SEPTIN9 and cancer.